Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weili He

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Asia-Pacific Journal of Clinical Oncology|April 20, 2010
Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastasesMark A Rosenthal, Peter Davidson, Frederic Rolland, et al.
Journal of Advanced Research|October 9, 2025
Corrigendum to "Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction" Adv. Res. 69 (2025) 399-411]Jiehuang Zheng, Weili He, Yan Chen, et al.
Journal of Advanced Research|March 31, 2024
Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destructionJiehuang Zheng, Weili He, Yan Chen, et al.
Current Medical Research and Opinion|September 14, 2006
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trialRobert Recker, Paul Lips, Dieter Felsenberg, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
DIA's Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for "Less Well-understood" Adaptive DesignsEva Miller, Paul Gallo, Weili He, et al.
Neurological Research|December 4, 2020
Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic strokeTao Qiu, Changqing Li, Linming Huang, et al.
Clinical and Translational Science|February 19, 2025
Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical PerspectiveJie Chen, Junrui Di, Nadia Daizadeh, et al.
Journal of Clinical Pharmacology|August 20, 2004
Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humansArthur J Bergman, Gail Murphy, Joanne Burke, et al.
Clinical Pharmacology and Therapeutics|March 13, 2025
Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical PerspectiveJie Chen, Lei Nie, Shiowjen Lee, et al.
Clinical Pharmacology and Therapeutics|February 14, 2025
Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical PerspectiveJie Chen, Susan Gruber, Hana Lee, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Asia-Pacific Journal of Clinical Oncology|April 20, 2010
Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastasesMark A Rosenthal, Peter Davidson, Frederic Rolland, et al.
Journal of Advanced Research|October 9, 2025
Corrigendum to "Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction" Adv. Res. 69 (2025) 399-411]Jiehuang Zheng, Weili He, Yan Chen, et al.
Journal of Advanced Research|March 31, 2024
Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destructionJiehuang Zheng, Weili He, Yan Chen, et al.
Current Medical Research and Opinion|September 14, 2006
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trialRobert Recker, Paul Lips, Dieter Felsenberg, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
DIA's Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for "Less Well-understood" Adaptive DesignsEva Miller, Paul Gallo, Weili He, et al.
Neurological Research|December 4, 2020
Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic strokeTao Qiu, Changqing Li, Linming Huang, et al.
Clinical and Translational Science|February 19, 2025
Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical PerspectiveJie Chen, Junrui Di, Nadia Daizadeh, et al.
Journal of Clinical Pharmacology|August 20, 2004
Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humansArthur J Bergman, Gail Murphy, Joanne Burke, et al.
Clinical Pharmacology and Therapeutics|March 13, 2025
Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical PerspectiveJie Chen, Lei Nie, Shiowjen Lee, et al.
Clinical Pharmacology and Therapeutics|February 14, 2025
Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical PerspectiveJie Chen, Susan Gruber, Hana Lee, et al.
Pageof 4